Hydralazine
- Generic Name
- Hydralazine
- Brand Names
- Apresoline, Bidil
- Drug Type
- Small Molecule
- Chemical Formula
- C8H8N4
- CAS Number
- 86-54-4
- Unique Ingredient Identifier
- 26NAK24LS8
- Background
Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed. Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure. Hydralazine is no longer a first line therapy for thes...
- Indication
Hydralazine is indicated alone or adjunct to standard therapy to treat essential hypertension. A combination product with isosorbide dinitrate is indicated as an adjunct therapy in the treatment of heart failure.
- Associated Conditions
- Heart Failure, Hypertension, Essential Hypertension, Hypertensive crisis, Severe Hypertension
- Associated Therapies
- -
Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
- Conditions
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Heart Center Research, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06218199
- Locations
- 🇺🇸
Heart Center Research, LLC, Huntsville, Alabama, United States
Blood Pressure Management in Stroke Following Endovascular Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT04484350
- Locations
- 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada
Efficacy of Nifedipine Versus Hydralazine in Management of Severe Hypertension in Pregnancy
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Adebayo Joshua Adeniyi
- Target Recruit Count
- 69
- Registration Number
- NCT04435210
- Locations
- 🇳🇬
Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Ebonyi, Nigeria
Blood Pressure After Endovascular Stroke Therapy-II
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 120
- Registration Number
- NCT04116112
- Locations
- 🇺🇸
Hartford Healthcare, Hartford, Connecticut, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 14
- Registration Number
- NCT03423810
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Changes in Central Arterial Pressure When Comparing ACOG Hypertensive Urgency Protocols
- Conditions
- Interventions
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- St. Louis University
- Registration Number
- NCT02933593
Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 100
- Registration Number
- NCT02343393
- Locations
- 🇸🇬
Changi General Hospital, Singapore, Singapore
🇸🇬National Heart Centre Singapore, Singapore, Singapore
🇸🇬National University Hospital, Singapore, Singapore, Singapore
Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.
- Conditions
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- Dow University of Health Sciences
- Target Recruit Count
- 190
- Registration Number
- NCT02050529
- Locations
- 🇵🇰
Civil Hospital Karachi, Karachi, Sindh, Pakistan
Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- University of Cape Town
- Target Recruit Count
- 500
- Registration Number
- NCT01822808
- Locations
- 🇿🇦
Hatter Institute for Cardiovascular Research in Africa, Cape Town, Western Cape, South Africa
Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2013-05-17
- Lead Sponsor
- Saint Thomas Hospital, Panama
- Target Recruit Count
- 261
- Registration Number
- NCT01538875
- Locations
- 🇵🇦
Saint Thomas Maternity Hospital, Panama, Panama
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.